Format

Send to

Choose Destination
Eur J Neurol. 2016 Feb;23(2):412-5. doi: 10.1111/ene.12922.

Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.

Author information

1
Department of Neurology and Medical Image Analysis Center, MIAC, University Hospital Basel, Basel, Switzerland.
2
DKD Helios Klinik Wiesbaden, Wiesbaden, Germany.
3
Department of Neurology, University of Colorado School of Medicine, Aurora, CO, USA.
4
Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
5
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
6
Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.
7
Department of Neurology, Medical University of Lodz, Lodz, Poland.
8
Department of Neurology, Rush University Medical Center, Chicago, IL, USA.
9
Biogen, Cambridge, MA, USA.

Abstract

BACKGROUND AND PURPOSE:

In the SELECT study, treatment with daclizumab high-yield process (DAC HYP) versus placebo reduced the frequency of gadolinium-enhancing (Gd(+) ) lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The objective of this post hoc analysis of SELECT was to evaluate the effect of DAC HYP on the evolution of new Gd(+) lesions to T1 hypointense lesions (T1 black holes).

METHODS:

SELECT was a randomized double-blind study of subcutaneous DAC HYP 150 or 300 mg or placebo every 4 weeks. Magnetic resonance imaging (MRI) scans were performed at baseline and weeks 24, 36 and 52 in all patients and monthly between weeks 4 and 20 in a subset of patients. MRI scans were evaluated for new Gd(+) lesions that evolved to T1 black holes at week 52. Data for the DAC HYP groups were pooled for analysis.

RESULTS:

Daclizumab high-yield process reduced the number of new Gd(+) lesions present at week 24 (P = 0.005) or between weeks 4 and 20 (P = 0.014) that evolved into T1 black holes at week 52 versus placebo. DAC HYP treatment also reduced the percentage of patients with Gd(+) lesions evolving to T1 black holes versus placebo.

CONCLUSIONS:

Treatment with DAC HYP reduced the evolution of Gd(+) lesions to T1 black holes versus placebo, suggesting that inflammatory lesions that evolved during DAC HYP treatment are less destructive than those evolving during placebo treatment.

KEYWORDS:

T1 black holes; daclizumab; gadolinium-enhancing lesions; magnetic resonance imaging; multiple sclerosis

PMID:
26806217
DOI:
10.1111/ene.12922
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center